Categories: Web and IT News

USPTO Grants Rare First-Action Allowance to Vital4 for AI Patent Underpinning Its Global Adverse Media Solution

Vital4 announces today a rare first-action allowance from the United States Patent and Trademark Office (USPTO) for “Systems and Processes for Contextualized Entity Resolution and Sentiment Analysis in Adverse Media Screening,” a major milestone in AI-driven risk and compliance innovation.

Vital4 announces a rare first-action allowance from the United States Patent and Trademark Office (USPTO) for “Systems and Processes for Contextualized Entity Resolution and Sentiment Analysis in Adverse Media Screening,” a major milestone in AI-driven risk and compliance innovation. The patent covers methods that use machine learning and natural language processing to link sentiment and adverse context to the correct entity in unstructured media, significantly improving screening precision at global scale.

“Receiving a first-action allowance from the USPTO is an exceptional validation of our approach to eliminating noise in adverse media,” said “Amy Barbieri,” Co-Founder, President, and Chief Growth Officer of Vital4. “This patent advances the Adverse Media 2.0 vision: cleaner, contextualized insights that let compliance teams move faster with confidence”.

Marketing Technology News: MarTech Interview with Stephen Howard-Sarin, MD of Retail Media, Americas @ Criteo

“This achievement reflects years of innovation from our team and partners,” said “Kristin Stafford,” Co-Founder and CEO of Vital4. “By tying adverse context to the right entity, we are setting a new standard for precision that protects customers from false positives, review fatigue, and missed risk”.

What the patent enables

  • Filters out articles where negative concepts are present but not tied to the screened person or business, reducing false positives across AML, KYC, Enhanced Customer Due Diligence, and third-party risk workflows.
  • Contextualizes entity mentions and enriches results with details like location and age enabling faster more accurate adjudication with minimal reviewer effort.

Proven impact

  • 97% reduction in irrelevant results and a 99% drop-in review time in a recent case study, enabling teams to double case reviews with the same headcount.
  • Measurable cost savings, stronger auditability, and reduced risk of regulatory penalties and reputational damage

Marketing Technology News: From MarTech Stack to MarTech Fabric: Weaving Brand, Content, and Conversion Into One Thread

The post USPTO Grants Rare First-Action Allowance to Vital4 for AI Patent Underpinning Its Global Adverse Media Solution first appeared on PressReleaseCC.

USPTO Grants Rare First-Action Allowance to Vital4 for AI Patent Underpinning Its Global Adverse Media Solution first appeared on Web and IT News.

awnewsor

Recent Posts

Freelancers, Avoid Tax Season Headaches with These Simple Steps by PayStubCreator

NEW YORK – Freelancers often face unique challenges during tax season. Unlike traditional employees who…

2 hours ago

Oligonucleotide CDMO Market to Hit $6.73 Billion by 2029 Amid Surge in Outsourced Gene-Based Drug Manufacturing

Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA, (CPG Oligos,…

2 hours ago

Retail Analytics Market Strategic Insights, Technological Advancements, Growth Drivers, Opportunities and Leading Key Vendors To 2031

Microsoft (US), IBM (US), SAP (Germany), Oracle (US), Salesforce (US), MicroStrategy (US), SAS Institute (US),…

2 hours ago

Digital Identity Solutions Market Latest Trends, Opportunities, Trends, Demand, Analysis and Future Outlook (2025-2031)

Digital Identity Solutions Market by Hardware (RFID Reader & Encoder, Hardware-Based Tokens, Processor ID Cards),…

2 hours ago

Latest Research on Battery Type in the Battery Energy Storage System (BESS) Market by MarketsandMarkets™

Battery Energy Storage System (BESS) Market The Battery Energy Storage System (BESS) Market is projected…

2 hours ago

Oligonucleotide Synthesis Market Projected to Reach $24.7 Billion by 2030 Driven by Expanding Genomics Applications

Oligonucleotide Synthesis Market by Product ((Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom,…

2 hours ago

This website uses cookies.